EyePoint

When it comes to matters of sight, innovation is our vision. We’re advancing a potential novel multi-mechanism of action for wet AMD and DME - the largest retinal disease markets where there is a significant need for new therapeutic options. See more on our programs: eyepoint.bio/our-programs/?…

Wet AMD remains a leading cause of vision loss. TKIs, like our lead investigational therapy, have the potential to reduce the need for frequent follow-up visits, while improving patient outcomes. See the story in @OPH360:  ophthalmology360.com/retina/tyrosin…

On this #NationalDoctorsDay, we proudly honor the exceptional principal investigators driving our pivotal Phase 3 clinical programs in wet AMD and DME. eyepoint.bio/our-programs/?…

Even with current anti-VEGF treatments, many people living with DME still face ongoing vision loss, underscoring the critical need for more durable therapies that also address inflammation. Learn more about our pivotal Phase 3 program: eyepoint.bio/our-programs/?…

#InvestorNews: #EYPT reports Q4 and full-year 2025 financial results and highlights recent corporate developments. See more on our latest pivotal Phase 3 trial progress and recent corporate updates here: investors.eyepoint.bio/news-releases/…

$EYPT announces first patient in Phase 3 DME clinical trials. 🔎The only sustained release TKI in Phase 3 clinical trials for DME 2️⃣ global, non-inferiority clinical trials, COMO & CAPRI 📈 Topline data expected 2H27 👉 Read more: investors.eyepoint.bio/news-releases/…

Wet AMD is the leading cause of vision loss and irreversible blindness in people over 50. This #AMDAwarenessMonth, #EYPT partners with @PBC_savingsight, reinforcing our commitment to improving vision and reducing the treatment burden for patients and caregivers.  preventblindness.org/2026-amd-low-v…

$EYPT welcomes Michael Campbell as CCO! With 30+ years of commercial leadership and a proven record of product launches, he will be instrumental as we work to potentially bring the first sustained release TKI to patients. Read more: investors.eyepoint.bio/news-releases/…

Team #EYPT kicked off January with impactful meetings nationwide. Thank you to the host organizations for creating spaces to share updates on our #WetAMD and DME clinical progress and learn from the latest innovations shaping the field. eyepoint.bio/%20?utm_source…

Our $EYPT team will be in San Francisco next month to present and connect with the investor community at the 44th annual J.P. Morgan Healthcare Conference. #JPM2026

Thank you to everyone who joined $EYPT at #FLORetina2025! It was an inspiring few days of scientific exchange, meaningful conversations, and collaboration across the retina community.

Drs. Sridhar, Mammo, and Sarraf are paid consultants of EyePoint; however, the statements made are the opinions of Drs. Sridhar, Mammo, and Sarraf for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.

Now live on your favorite podcast platform, EyePoint presents a three-part series hosted by Jayanth Sridhar, M.D. on New Retina Radio by @eyetubenet. 🎧Tune in to hear from retina specialists on the variations in retinal thickness and how to protect patients’ vision for the long term. eyetube.net/podcasts/new-r…

Excited to join FLORetina-ICOOR 2025 next week! We’ll share updates and connect with the retina community on advancing care in wet AMD and DME. Check the program for presentation times: floretina.com/floretinaicoor… #FLORetina2025

With the most extensively studied TKI in retinal disease, robust safety data, and no TIE2 inhibition, we’re advancing a potential novel mechanism of action for wet AMD treatment — driven by science, guided by patient needs. Learn more about our progress: eyepointpharma.com/our-programs/

EyePoint is proud to announce the positive recommendation from the independent Data Safety Monitoring Committee for our pivotal Phase 3 wet AMD program. 📈 Topline LUGANO data expected mid-2026 with LUCIA to closely follow. 👉 Read more: investors.eyepointpharma.com/news-releases/…

One year later at our Northbridge, MA facility and we are only continuing to grow — soon adding 30 new roles for our site! Explore careers: eyepointpharma.com/working-at-eye… #LifeSciences #Hiring #MassachusettsJobs #Northbridge

The #EYPT team is heading to #NYC for this week’s @Healio_OSN Retina Meeting! We look forward to connecting with the retina community at #OSNNYandRetina to share more about our pivotal Phase 3 wet AMD and DME programs.